Skip to main content

Search This Blog

Pulmonary Hypertension

Posts

Resuscitated Cardiac Arrest: Dynamic Mitral Regurgitation Treated With Transapical Valve Replacement

Get link
Facebook
X
Pinterest
Email
Other Apps

September 20, 2026

Invalid Access Key! Invalid Access Key!

HFpEF: Heart Failure with Preserved Ejection Fraction

Get link
Facebook
X
Pinterest
Email
Other Apps

September 20, 2026

Invalid Access Key! Invalid Access Key!

Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024

Get link
Facebook
X
Pinterest
Email
Other Apps

September 20, 2026

Invalid Access Key! Invalid Access Key!

Cardiovascular Hypertensive Crisis: Recent Evidence and Review of the Literature

Get link
Facebook
X
Pinterest
Email
Other Apps

September 19, 2026

Invalid Access Key! Invalid Access Key!

Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024

Get link
Facebook
X
Pinterest
Email
Other Apps

September 19, 2026

Invalid Access Key! Invalid Access Key!

Pulmonary Hypertension: Diagnosis and Treatment

Get link
Facebook
X
Pinterest
Email
Other Apps

September 18, 2026

Invalid Access Key! Invalid Access Key!

Clinical features of pulmonary arterial hypertension associated with systemic sclerosis

Get link
Facebook
X
Pinterest
Email
Other Apps

September 18, 2026

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Theme images by 4x6

Archive

September44
August59
July47
June22
May41
April32
March70
February59
January81
December24

Show more Show less

Popular posts from this blog

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle - Qu - 2025 - ESC Heart Failure

esc hf 2023 :: Article Creator ESC Focused Update On HF Synthesizes New Trial Data For Practical Use More than a dozen new RCTs dedicated to acute and chronic heart failure (HF) have come out over the course of just the past few years since the 2021 European Society of Cardiology (ESC) Guidelines on the topic—the time was ripe for a focused update, the writing committee said last week. "We felt we had to do an update because heart failure is obviously a rapidly changing field," said guideline chair Theresa A. McDonagh, MD (King's College Hospital, London, England), who presented the latest recommendations in a Hot Line session at the ESC Congress 2023 in Amsterdam, the Netherlands. The update, which featured advice for treatment and diagnosis, was simultaneously published in the European Heart Journal. Among the influential trials up for consideration across the spectrum of acute HF, chronic HF, and comorbidities were ADVOR, COAC...

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Overview Shortness of breath (dyspnea) is most commonly caused by heart or lung conditions. Other causes include anemia, anxiety, lack of exercise or living with obesity. What is dyspnea (shortness of breath)? Dyspnea (pronounced "DISP-nee-uh") is the word healthcare providers use for feeling short of breath. You might describe it as not being able to get enough air ("air hunger"), chest tightness or working harder to breathe. Shortness of breath is often a symptom of heart and lung problems. But it can also be a sign of other conditions like asthma, allergies or anxiety. Intense exercise or having a cold can also make you feel breathless. What are paroxysmal nocturnal dyspnea (PND) and sighing dyspnea? Paroxysmal nocturnal dyspnea (PND) is a feeling like you can't breathe an hour or two after falling asleep. Sighing dyspnea is when you sigh a lot after taking deep breaths in to try to relieve the feeling of dyspnea. What is the differ...

Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News

Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Posted: 02 Mar 2020 12:00 AM PST Aria CV announced the end of a funding round that will be used to finance a feasibility study of its medical device, the Pulmonary Hypertension System (Aria CV PH System), in people with pulmonary arterial hypertension (PAH) in the U.S. The series B round, which raised $31 million, was led by Xeraya Capital . "Aria CV is now well positioned to drive our clinical research forward," Dan Gladney, the company's chief executive officer and president, said in a press release . "We are grateful for this validation by our investors and remain committed to bringing this innovative treatment option to PAH patients," Gladney added. Pulmonary hyperte...

Labels

"pulmonary hypertension prognosis" - Google News
idiopathic pulmonary hypertension
IFTTT
mild pulmonary hypertension
pulmonary artery hypertension
Pulmonary Hypertension
pulmonary hypertension causes
pulmonary hypertension diagnosis
pulmonary hypertension medications
pulmonary hypertension prognosis

pulmonary hypertension symptoms
pulmonary hypertension treatment
severe pulmonary hypertension
what is pulmonary hypertension

Show more Show less

yand